ArticleClinical rheumatology2026
The utility of rituximab in patients with eosinophilic fasciitis: case series from an Australian tertiary multidisciplinary clinic.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review.Rheumatology international · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEosinophilic fasciitis (EF) is a rare condition characterised by sclerosis of the skin, fascia and subcutaneous tissues. We aimed to review cases of EF managed in a multidisciplinary clinic from an Australian tertiary hospital, highlighting clinical characteristics, treatment approaches including success with rituximab and the benefits of a multidisciplinary approach.
methodPatients with EF (Pinal-Fernandez and/or Jinnin criteria) managed in the inflammatory skin clinic between 01/22 and 07/25 at Flinders Medical Centre, South Australia, were identified. Clinical characteristics (timeline/extent of skin involvement, extracutaneous symptoms, time-to-diagnosis), laboratory investigations, imaging, histology and treatment exposures were reviewed.
resultsFive patients with EF were identified; 4/5 were female, and the mean age was 60 years. Time-to-diagnosis ranged from 3 to 18 months. Four patients had upper and lower limb involvement; one had upper limb involvement only. Skin tightness universally impaired the range of motion of affected joints. Peripheral eosinophilia was present in 4/5 patients. Of the three patients who underwent MRI, two showed myoedema with fascial thickening. Eosinophils were present on incisional skin biopsy in 4/5 patients. Although methotrexate and mycophenolate were frequently trialled, 4/5 patients required escalation to rituximab. Over 11-36 months of follow-up, all patients demonstrated significant improvement in skin thickening, symptoms and function.
conclusionsWe have reported the first Australian single-centre cohort of patients with EF. Although not universal, peripheral eosinophilia and eosinophils on skin biopsy frequently occurred. Muscle involvement, constituting myofasciitis, was common. Rituximab appears to be an efficacious treatment with a potentially durable response to induction without requiring maintenance dosing. At our centre, a multidisciplinary approach has assisted in accurately diagnosing EF and appropriately escalating treatment.
Indexed as
Identifiers
41331198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.